Deutsche
Gesellschaft
für Nuklearmedizin
e.V.

Translational Research in Molecular Imaging and Radionuclid Therapy

August 27 - 29, 2015

Oncology

Dr. Agnieszka Morgenroth

Klinik für Nuklearmedizin,
Universitätsklinikum Aachen

Oncology
Hallmarks of Cancer as diagnostic and therapeutic Targets



Hanahan et al. Cell 2011

Oncology
Reprogramming Energy Metabolism as „core“ hallmark capability of cancer cells

Deregulation cellular energetics

Switch in cancer cells towards increased metabolic rate of:

- glucose
- amino acids
- lipids

Oncology
Metabolic switch: one hallmark many faces



Oncology
Metabolic switch: one hallmark many faces



Mechanism beyond the metabolic switch:

- Growth or survival factor signaling activates the PI3K signaling pathway.
- Activated PI3K activates AKT, which then activates mTOR, which then activates HIF.
- HIF moves into the nucleus of the cell and activates genes that promote aerobic glycolysis while repressing normal metabolism.
- Activated PI3K can be attenuated by tumor suppressor protein PTEN.



^{18}F-FDG PET/CT



18F-FDG PET/CT in **clinical** routine:

- staging and restaging of a variety of malignant tumors, including lymphoma, melanoma, non–small cell lung cancer, esophageal cancer, and colorectal cancer

- monitoring tumor response to therapy

Oncology
Metabolic switch: one hallmark many faces



^{18}F-FDG PET/CT

18F-FDG PET/CT in **pre-clinical** routine:

- evaluation of tumor growth *in vivo*
- monitoring tumor response to therapy



Representative decay-corrected whole-body coronal microPET images of mice bearing UM-SCC-22B tumors at 1 h after intravenous injection of ^{18}F-FDG (1.85 MBq/mouse) **after Doxil** or PBS treatment.

Zhang et al. Theranostics 2011



Representative decay-corrected whole-body coronal microPET images of mice bearing MDA-MB 231 tumors at 0.5h after intravenous injection of ^{18}F-FDG (1.5 MBq/mouse) **7 and 14 days after xenotransplantation**.

Morgenroth et al. unpublished data

Oncology
Metabolic switch: one hallmark many faces

Metabolic reprogramming causes some cancers to switch their energy source from glucose to glutamine…



Rationale for glutamine as an alternative energy source:

- highest concentration (0.5–1 mM) among all of the amino acids circulating in the blood

- during period of rapid growth or stress increased demand for glutamine supply

- contributes to both of energy forming pathways in cancer cells: oxidative phosphorylation and glycolysis

Hensley et al. J Clin Invest 2013

Oncology
Metabolic switch: one hallmark many faces

glutamine



[18F](2S,4R)4-fluoroglutamine
(2S,4R)4-FGln



Development of glutamine-derivatives as PET tracer for:

- molecular imaging of FDG-negative glutamine-addicted tumors (neuroblastoma)
- identification of patients responding to inhibitors of glutamine metabolism (therapy planning)





In Vivo Biodistribution of ^{18}F-(2S,4R)4-Fluoroglutamine in F344 Rats Bearing 9L Tumor Xenografts After Intravenous Injection

Organ	30 min	60 min
Blood	0.43 ± 0.01	0.32 ± 0.02
Heart	0.36 ± 0.02	0.35 ± 0.01
Muscle	0.37 ± 0.02	0.38 ± 0.03
Lung	0.64 ± 0.02	0.41 ± 0.04
Kidney	1.02 ± 0.12	0.76 ± 0.18
Pancreas	2.14 ± 0.27	1.36 ± 0.16
Spleen	0.76 ± 0.05	0.53 ± 0.04
Liver	0.98 ± 0.15	0.66 ± 0.13
Skin	0.42 ± 0.11	0.29 ± 0.04
Brain	0.11 ± 0.01	0.13 ± 0.00
Bone	0.78 ± 0.13	1.03 ± 0.38
Tumor 9L (n = 5)	1.03 ± 0.14	0.76 ± 0.21
Ratio		
Tumor to blood	2.39	2.37
Tumor to muscle	2.78	2.00

Lieberman et al. J Nucl Med 2011

Oncology
Metabolic switch: one hallmark many faces

The fat side of cancer:
Increased de novo synthesis of fatty acids as source of energy, constituents for cell membrane and modification of proteins.



Glunde et al. Neture Rev 2011

Choline as target for molecular imaging of cancer:

- Enhanced choline uptake and intracellular turnover of phosphatidylcholine in many malignant tumors (prostate, breast, ovarian) due to overexpression of choline transporter and choline kinase

Oncology
Metabolic switch: one hallmark many faces



^{18}F-Choline PET/CT



18F-Cholin PET/CT in **clinical** routine:

- diagnosis and staging of patients with primary prostate cancer

- monitoring tumor response to therapy







Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Sustaining proliferative signaling

Evading growth suppressors

Cancer cells acquire the capability to sustain proliferative signaling:

- by increased production of growth factors e.g. EGF, IGF-1 (autonomous growth)
- by overexpression of cognate receptors e.g. EGFR, IGF-1R (hypersensitivity)
- by somatic mutations of signaling pathways operating downstream of growth receptors e.g. B-Raf, PI3-K (constitutive activation)
- by disruption of regulatory negative-feedback mechanism and inactivation of growth suppressors e.g RB protein, TP53 (uncontrolled proliferation)

Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Sustained and continued demand on supply of DNA building blocks as tumor specific target



Highly increased expression and activity of thymidine kinase during the S-phase in malignant cells



Highly increased expression of nucleoside transporter hENT1 in malignant cells



Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Nucleoside analogues for molecular imaging and therapy of cancer



Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

^{18}F-FLT PET/CT





McKinley et al. PLOS ONE 2013



18F-FLT PET/CT in **clinical** routine:

- diagnosis and staging of a variety of malignant tumors
- monitoring tumor response to therapy



Herrmann et al. J Nucl Med 2011

Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Nucleoside analogues for molecular imaging and therapy of cancer



Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Preclinical evaluation of nucleoside analogue ITdU for endogenous therapy

Table 1. Phosphorylation of 5-iodonucleosides by TK1 and susceptibility to glycosidic bond cleavage by TP

Substrate	Phosphorylation rate*	Relative activity †	Formation of IU ‡	Relative activity †
IdUrd	270 ± 5	1.00	7.8 ± 0.2	1.00
ITdU	125 ± 2	0.46 ± 0.01	0.280 ± 0.002	0.036 ± 0.001

*Phosphorylation rate: nmol monophosphate/(mg TK1 × min).
† Relative activity normalized to IdUrd.
‡ Formation of IU: µmol IU/(unit TP × min).



Morgenroth et al. Clin Cancer Res 2008

Biochemical features of ITdU (5-iodo-4´-thio-2-desoxyuridin):

- phosphorylated by thymidine kinase 1
- no enzymatic degradation by thymidine phosphorylase
- 5-Fluor-2´-desoxyuridin (FdUrd) -dependent cell uptake and incorporation into DNA of proliferating tumor cells
- DNA-incorporated [125I]ITdU induces efficiently apoptosis in more than 90% of tumor cells causing extensive tissue damage

Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Preclinical evaluation of nucleoside analogue $^{123/125}$I-ITdU for endogenous therapy

SPECT 24h p.i. of ^{123}I-ITDU



Microautoradiography and TUNEL analysis 24h p.i. of ^{125}I-ITDU



Survival curve (single application of ^{125}I-ITDU)



Morgenroth et al. Clin Cancer Res 2008

Oncology
Chronic cell proliferation: most fundamental trait of cancer cells



Morgenroth et al. submitted

Oncology
Cancer stem cells – a new target for ITdU

Unique properties of stem cells

- Dormancy
- **high mitotic activity** (inducible in response to „injury-signals“)
- asymmetric division:
  - Self-renewal
  - Differentiation potential
- active signaling pathways essential for maintenance of „self-renewal“ capacity like Hedgehog (Hh), Wnt und Notch
- resistance to drugs and toxins through expression of several ABC transporters, an active DNA-repair capacity and resistance to apoptosis



Oncology
Cancer stem cells – a new target for ITdU



Huse J. et al. Nature Rev 2010

Current Biology 17, 165–172, January 23, 2007 ©2007 Elsevier Ltd All rights reserved DOI 10.1016/j.cub.2006.11.033

Report

HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and Tumorigenicity

Virginie Clement,[1] Pilar Sanchez,[1,3] Nicolas de Tribolet,[2] Ivan Radovanovic,[2] and Ariel Ruiz i Altaba[1,*]



Takezaki T. et al. Cancer Sci 2011

Oncology
Cancer stem cells – a new target for ITdU

Proliferation Induction of dormant TSC by Stimulation of Hh Pathway with the Sonic Hedgehog Ligand Shh



Figure 6: A two-step killing strategy of glioblastoma multiforme stem cells. Glioma stem cells are activated by HH signaling pathway to enter mitosis. The proliferating glioma stem cells incorporate the radiolabelled thymidine analogue [I-125]ITdU into the DNA via the salvage pathway. This effect is further enhanced by simultaneous FdUrd mediated inhibition of the *de novo* pathway of thymidine synthesis.

Morgenroth A et al. Oncotargets 2014

Oncology
Cancer stem cells – a new target for ITdU



Effect of SHH stimulation on proliferation of glioma cells and normal astrocytes. (A) Percentage of BrdU+ R8, R18, R28 cells and normal human astrocytes (NHA) after stimulation with SHH in comparison with unstimulated cells. (B) Phase-contrast images (i, iv) and fluorescent images after staining with BODIPY-Cyclopamine (anti- Smo, green; ii, v) and anti-BrdU antibody (green; iii, vi) of unstimulated and SHH stimulated R28 neurospheres (Hoechst nuclei staining in blue).

Clonogenic survival of $CD133^-$ and $CD133^+$ R28 cells after incubation with [I-125]ITdU in dependency on FdUrd and SHH stimulation.



Morgenroth A et al. Oncotargets 2014

Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Preclinical evaluation of nucleoside analogue 3'-(E)-(2-Iodovinyl)uridin (IV-14)





Rationale for development of RNA-addressing nucleoside analogues

- for targeting of tumors with low mitotic index
- RNA-synthesis not S-phase restricted
- Uridine Cytidine Kinase 2 (UCK2) highly overexpressed in pancreas, colon, breast, lung, and ovarian tumor tissues

Oncology
Chronic cell proliferation: most fundamental trait of cancer cells

Preclinical evaluation of nucleoside analogue 3'-(E)-(2-Iodovinyl)uridin (IV-14)









Zlatopolskiy et al. JNM 2009

Oncology
Inflammation as an early step of neoplastic progression

Tumor-promoting inflammation

- Chronic infection and inflammation cause cancer in several organs including the colon, liver and large intestine.
- Tumor-promoting inflammatory cells (macrophages, mast cells, neutrophils, T- and B-cells) release signaling molecules (e.g. EGF, VEGF, FGF2, chemokines, cytokines) and pro-invasive matrix-degrading enzymes (MMP-9).
- Inflammatory cells (macrophages) release reactive oxygen species that are actively mutagenic for nearby cancer cells.

Tumor-infiltrating inflammatory cells induce and support tumor angiogenesis, proliferation of malignant cells, and facilitate tissue invasion.

Oncology
Inflammation as an early step of neoplastic progression

Tumor promoting function in carcinogenesis of cyclooxygenase-2 (COX-2)



Gupta et al. Nature Rev 2001

Tumorigenesis supporting mechanisms

- COX-2 produced prostaglandins cause resistance to apoptosis and enhance cell migration in cancer cells (cell-autonomous effect)
- COX-2 induces production of pro-angiogenic growth factors in fibroblasts and supports migration of endothelial cells (neovascularization)

Oncology
Inflammation as an early step of neoplastic progression



Bertolini et al. *Pharmacol Res* (2001)

Pre-clinical evaluation of Indomethacin-Derivatives as PET/SPECT tracer for molecular imaging of colorectal carcinoma







HT29 Xenograft (COX-2$^+$)



HCT-116 Xenograft (COX-2$^-$)







Morgenroth et al. unpublished data

SUMMER SCHOOL 2015

Oncology
Hallmarks of Cancer: new tumor-associated targets




Thank you for your attention!!!
Any questions?